inflammation

Glowing puzzle piece fitting into puzzle
Biotech

Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million for the rights to Vanqua Bio’s preclinical C5aR1 antagonist.
James Waldron Oct 24, 2025 9:15am
Lifeline

HCW Biologics clings on with $5M lifeline to fund alopecia trial

May 16, 2025 7:00am
lion roaring

Gilead roars into JPM25 with $250M upfront deal for Leo

Jan 11, 2025 5:30pm
reshuffle pipeline target reorganize shift change

Celldex drops phase 1 tumor bispecific to focus on inflammation

Nov 7, 2024 7:25am
pay deal hand over cash licensing transaction money

Ocean Biomedical pens $32M pact for Polish YKL-40 inhibitors

Oct 15, 2024 10:05am
GSK

GSK blockbuster hope depemokimab shrinks polyps in ph. 3 trials

Oct 14, 2024 4:51am